# S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

> **NCT00897091** · — · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 750 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **GENETIC:** comparative genomic hybridization
- **GENETIC:** microarray analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** diagnostic laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00897091
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2013-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00897091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00897091, "S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00897091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*